Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections

被引：5

作者：

Cojutti, Pier Giorgio ^{[1
,2
]}

Gatti, Milo ^{[1
,2
]}

Punt, Nieko ^{[3
,4
]}

Dousa, Jiri ^{[5
,6
]}

Zamparini, Eleonora ^{[1
,7
]}

Tedeschi, Sara ^{[1
,7
]}

Viale, Pierluigi ^{[1
,7
]}

Pea, Federico ^{[1
,2
]}

机构：

[1] Univ Bologna, Dept Med & Surg Sci, Alma Mater Studiorum, Bologna, Italy

[2] IRCCS Azienda Osped Univ Bologna, Clin Pharmacol Unit, Bologna, Italy

[3] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

[4] Medimatics, Maastricht, Netherlands

[5] Charles Univ Prague, Fac Med 1, Dept Pharmacol & Toxicol, Prague, Czech Republic

[6] Mediware As, Prague, Czech Republic

[7] IRCCS Azienda Osped Univ Bologna, Infect Dis Unit, Bologna, Italy

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2024年 / 63卷 / 01期

关键词：

TDM; dalbavancin; Bayesian prediction; MwPharm; SOFTWARE;

D O I：

10.1016/j.ijantimicag.2023.107038

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Dalbavancin is increasingly being used for long-term treatment of subacute and chronic staphylococcal infections. In this study, a new Bayesian model was implemented and validated using MwPharm soft-ware for accurately forecasting the duration of pharmacodynamic target attainment above the efficacy thresholds of 4.02 mg/L or 8.04 mg/L against staphylococci. Forecasting accuracy improved substantially with the a posteriori approach compared with the a priori approach, particularly when two measured concentrations were used. This strategy may help clinicians to estimate the duration of optimal exposure with dalbavancin in the context of long-term treatment.(c) 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

引用

页数：5